Asarm peptides: PHEX-dependent and -independent regulation of serum phosphate

American Journal of Physiology - Renal Physiology

Volumn 300, Issue 3, 2011, Pages

  David, Valentin ^a   Martin, Aline ^a   Hedge, Anne Marie ^b   Drezner, Marc K ^c   Rowe, Peter S N ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

1; 25 dihydroxy vitamin D3; Dentin matrix protein 1; Fibroblast growth factor 23; Matrix extracellular phosphoglycoprotein; Mineralization; Osteomalacia; SIBLING proteins; X linked hypophosphatemic rickets

Indexed keywords

COLECALCIFEROL; COTRANSPORTER; FIBROBLAST GROWTH FACTOR 23; MESSENGER RNA; OSTEOCALCIN; OSTEOPONTIN; PARATHYROID HORMONE; PEPTIDE DERIVATIVE; PHOSPHATE; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PHOSPHORUS; PROTEIN ASARM; PROTEIN NPT2A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CONTROLLED STUDY; HYPOPHOSPHATEMIA; HYPOPHOSPHATEMIC RICKETS; MALE; MOUSE; NONHUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; VITAMIN SUPPLEMENTATION; WILD TYPE;

EID: 79954540547     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00304.2010     Document Type: Article

References (66)

1. Addison W, Masica D, Gray J, McKee MD. Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J Bone Miner Res 25: 695-705, 2009.
2. Addison W, Nakano Y, Loisel T, Crine P, McKee M. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hy-droxyapatite-an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res 23: 1638-1649, 2008.
3. Argiro L, Desbarats M, Glorieux FH, Ecarot B. Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteo-malacia, is expressed in bone. Genomics 74: 342-351, 2001.
4. Bai X, Miao D, Panda D, Grady S, McKee MD, Goltzman D, Karaplis AC. Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression. Mol Endocrinol 16: 2913-2925, 2002.
5. Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8: 212-226, 2008.
6. Bonjour JP, Trechsel U, Fleisch H, Schenk R, DeLuca HF, Baxter LA. Action of 1,25-dihydroxyvitamin D3 and a diphosphonate on calcium metabolism in rats. Am J Physiol 229: 402-408, 1975.
7. Boskey AL, Chiang P, Fermanis A, Brown J, Taleb H, David V, Rowe PS. MEPE's diverse effects on mineralization. Calcif Tissue Int 86: 42-46, 2009.
8. Boukpessi T, Septier D, Bagga S, Garabedian M, Goldberg M, Chaussain-Miller C. Dentin alteration of deciduous teeth in human hypophosphatemic rickets. Calcif Tissue Int 79: 294-300, 2006.
9. Bresler D, Bruder J, Mohnike KL, Fraser D, Rowe PSN. Serum MEPE-ASARM peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol 183: R1-R9, 2004.
10. Campos M, Couture C, Hirata IY, Juliano MA, Loisel TP, Crine P, Juliano L, Boileau G, Carmona AK. Human recombinant endopeptidase PHEX has a strict S1= specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phos-phoglycoprotein. Biochem J 373: 271-279, 2003.
11. Chau H, El-Maadawy S, McKee MD, Tenenhouse HS. Renal calcification in mice homozygous for the disrupted type IIa Na/Pi cotransporter gene Npt2. J Bone Miner Res 18: 644-657, 2003.
12. Chien YC, Masica DL, Gray JJ, Nguyen S, Vali H, McKee MD. Modulation of calcium oxalate dihydrate growth by selective crystal-face binding of phosphorylated osteopontin and polyaspartate peptide showing occlusion by sectoral (compositional) zoning. J Biol Chem 284: 23491-23501, 2009.
13. David V, Martin A, Hedge AM, Rowe PS. Matrix extracellular phos-phoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology 150: 4012-4023, 2009.
14. Dobbie H, Unwin RJ, Faria NJ, Shirley DG. Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption. Nephrol Dial Transplant 23: 730-733, 2008.
15. Drezner MK. Hypophosphatemic rickets. Endocr Dev 6: 126-155, 2003.
16. Dubois SG, Ruchon AF, Delalandre A, Boileau G, Lajeunesse D. Role of abnormal neutral endopeptidase-like activities in Hyp mouse bone cells in renal phosphate transport. Am J Physiol Cell Physiol 283: C1414-C1421, 2002.
17. Fedarko NS, Jain A, Karadag A, Fisher LW. Three small integrin-binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB J 18: 734-736, 2004.
18. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38: 1310-1315, 2006.
19. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 280: 460-465, 2001.
20. Guo R, Rowe PS, Liu S, Simpson LG, Xiao ZS, Quarles LD. Inhibition of MEPE cleavage by Phex. Biochem Biophys Res Commun 297: 38-45, 2002.
21. Hamamoto S, Nomura S, Yasui T, Okada A, Hirose M, Shimizu H, Itoh Y, Tozawa K, Kohri K. Effects of impaired functional domains of osteopontin on renal crystal formation: analyses of OPN transgenic and OPN knockout mice. J Bone Miner Res 25: 2436-2447, 2010.
22. Harris SE, Gluhak-Heinrich J, Harris MA, Yang W, Bonewald LF, Riha D, Rowe PS, Robling AG, Turner CH, Feng JQ, McKee MD, Nicollela D. DMP1 and MEPE expression are elevated in osteocytes after mechanical loading in vivo: theoretical role in controlling mineral quality in the perila-cunar matrix. J Musculoskelet Neuronal Interact 7: 313-315, 2007.
23. Hoyer JR, Asplin JR, Otvos L. Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int 60: 77-82, 2001.
24. HYP consortium, Francis F, Hennig S, Korn B, Reinhardt R, de Jong D, Poustka A, Lehrach H, Rowe PSN, Goulding JN, Summerfield T, Mountford RC, Read AP, Popowska E, Pronicka E, Davies KE, ÓRiordan JLH, Econs MJ, Nesbitt T, Drezner MK, Oudet C, Pan-netier S, Hanauer A, Strom TM, Meindl A, Lorenz B, Cagnoli M, Mohnike KL, Murken J, Meitinger T. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 11: 130-136, 1995.
25. Jain A, Fisher LW, Fedarko NS. Bone sialoprotein binding to matrix metalloproteinase-2 alters enzyme inhibition kinetics. Biochemistry 47: 5986-5995, 2008.
26. Jiang B, Cao Z, Lu Y, Janik CB, Lauziere S, Xie Y, Poliard A, Qin C, Ward LM, Feng JQ. DMP1 C-terminal mutant mice recapture the human ARHR tooth phenotype. J Bone Miner Res 25: 2155-2164, 2010.
27. Kiela PR, Ghishan FK. Recent advances in the renal-skeletal-gut axis that controls phosphate homeostasis. Lab Invest 89: 7-14, 2009.
28. Lawson-Matthew PJ, Guilland-Cumming DF, Yates AJ, Russell RG, Kanis JA. Contrasting effects of intravenous and oral etidronate on vitamin D metabolism in man. Clin Sci (Lond) 74: 101-106, 1988.
29. Liu S, Brown TA, Zhou J, Xiao ZS, Awad H, Guilak F, Quarles LD. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 16: 1645-1653, 2005.
30. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD. Regulation of FGF23 expression but not degradation by phex. J Biol Chem 278: 37419-37426, 2003.
31. Liu S, Rowe PS, Vierthaler L, Zhou J, Quarles LD. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol 192: 261-267, 2007.
32. +-phosphate cotransport in opossum kidney cells. Am J Physiol Renal Fluid Electrolyte Physiol 263: F301-F310, 1992.
33. Loghman-Adham M, Szczepanska-Konkel M, Dousa TP. Phosphate transport in brush border membranes from uremic rats. Response to phosphonoformic acid. J Am Soc Nephrol 3: 1253-1259, 1992.
34. +-Pi cotransporter in small gut brush border by phosphonocarboxylic acids. Am J Physiol Gastrointest Liver Physiol 252: G244-G249, 1987.
35. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, Amyere M, Wagen-staller J, Muller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Shlossberg AH, Olivares JL, Loris C, Ramos FJ, Glorieux F, Vikkula M, Juppner H, Strom TM. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38: 1248-1250, 2006.
36. Marks J, Churchill LJ, Edward SD, Unwin R. The phosphatonin matrix extracellular phosphoglycoprotein (MEPE) inhibits renal intestinal phosphate transport in vivo. J Am Soc Nephrol 19: 2313-2320, 2008.
37. Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge AM, Rowe PS. Degradation of MEPE, DMP1, and release of SIBLING ASARM peptides (minhibins): ASARM peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 149: 1757-1772, 2008.
38. Matsumoto N, Jo OD, Shih RN, Brochmann EJ, Murray SS, Hong V, Yanagawa J, Yanagawa N. Increased cathepsin D release by Hyp mouse osteoblast cells. Am J Physiol Endocrinol Metab 289: E123-E132, 2005.
39. Matsumoto N, Jo OD, Shih RN, Yanagawa N. Altered cathepsin D metabolism in PHEX antisense human osteoblast cells. Biochem Biophys Res Commun 332: 248-253, 2005.
40. McCloskey EV, Yates AJ, Beneton MN, Galloway J, Harris S, Kanis JA. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone 8: S35-S41, 1987.
41. McCloskey EV, Yates AJ, Gray RE, Hamdy NA, Galloway J, Kanis JA. Diphosphonates and phosphate homeostasis in man. Clin Sci (Lond) 74: 607-612, 1988.
42. Muhlbauer RC, Bonjour JP, Fleisch H. Tubular handling of phosphate along the nephron of thyroparathyroidectomized rats injected with ethane-1-hydroxy-1,1-diphosphonate. Clin Sci (Lond) 60: 171-177, 1981.
43. Okada A, Nomura S, Saeki Y, Higashibata Y, Hamamoto S, Hirose M, Itoh Y, Yasui T, Tozawa K, Kohri K. Morphological conversion of calcium oxalate crystals into stones is regulated by osteopontin in mouse kidney. J Bone Miner Res 23: 1629-1637, 2008.
44. Okano T, Tsugawa N, Hirami C, Kato S. Functional properties of cultured normal and vitamin D receptor knockout mice calvarial osteoblasts (Abstract). J Bone Miner Res 18, Suppl 2: S141, 2003.
45. Prie D, Torres PU, Friedlander G. Latest findings in phosphate homeostasis. Kidney Int 4: 1-8, 2009.
46. Qin C, D'Souza R, Feng JQ. Dentin matrix protein 1 (DMP1): new and important roles for biomineralization and phosphate homeostasis. J Dent Res 86: 1134-1141, 2007.
47. Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67: 54-68, 2000.
48. Rowe PS, Matsumoto N, Jo OD, Shih RN, Oconnor J, Roudier MP, Bain S, Liu S, Harrison J, Yanagawa N. Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin. Bone 39: 773-786, 2006.
49. Rowe PSN. The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med 15: 264-281, 2004.
50. Rowe PSN, de Zoysa P, Dong R, Wang H, White K, Econs M, Oudet C. MEPE, a new gene expressed in bone marrow and tumours causing osteomalacia. Genomics 67: 54-68, 2000.
51. Rowe PSN, Garrett IR, Schwarz PM, Carnes DL, Lafer EM, Mundy GR, Gutierrez GE. Surface plasmon resonance (SPR) confirms MEPE binds to PHEX via the MEPE-ASARM-motif: a model for impaired mineralization in X-linked rickets (HYP). Bone 36: 33-46, 2005.
52. Rowe PSN, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR. MEPE has the properties of an osteoblastic Phosphatonin and Minhibin. Bone 34: 303-319, 2004.
53. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280: 2543-2549, 2005.
54. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 150: 4835-4845, 2009.
55. Shih NR, Jo OD, Yanagawa N. Effects of PHEX antisense in human osteoblast cells. J Am Soc Nephrol 13: 394-399, 2002.
56. Shirley DG, Faria NJ, Unwin RJ, Dobbie H. Direct micropuncture evidence that matrix extracellular phosphoglycoprotein inhibits proximal tubular phosphate reabsorption. Nephrol Dial Transplant 25: 3191-3195, 2010.
57. Stoll R, Fleisch H, Bonjour JP. Effect of diphosphonate treatment on phosphate transport by renal brush-border vesicles. Am J Physiol Renal Fluid Electrolyte Physiol 239: F13-F16, 1980.
58. +-dependent transport of phosphate across renal brush border membrane. J Biol Chem 261: 6375-6383, 1986.
59. Tenenhouse HS. Phosphate transport: molecular basis, regulation and pathophysiology. J Steroid Biochem Mol Biol 103: 572-577, 2007.
60. Trechsel U, Schenk R, Bonjour JP, Russell RG, Fleisch H. Relation between bone mineralization, Ca absorption, and plasma Ca in phospho-nate-treated rats. Am J Physiol Endocrinol Metab Gastrointest Physiol 232: E298-E305, 1977.
61. VanScoy M, Loghman-Adham M, Onsgard M, Szczepanska-Konkel M, Homma S, Knox FG, Dousa TP. Mechanism of phosphaturia elicited by administration of phosphonoformate in vivo. Am J Physiol Renal Fluid Electrolyte Physiol 255: F984-F994, 1988.
62. Walsh SB, Shirley DG, Wrong OM, Unwin RJ. Urinary acidification assessed by simultaneous furosemide and fludrocortisone treatment: an alternative to ammonium chloride. Kidney Int 71: 1310-1316, 2007.
63. Walton RJ, Russell RG, Smith R. Changes in the renal and extrarenal handling of phosphate induced by disodium etidronate (EHDP) in man. Clin Sci Mol Med 49: 45-56, 1975.
64. Wang L, Guan X, Tang R, Hoyer JR, Wierzbicki A, De Yoreo JJ, Nancollas GH. Phosphorylation of osteopontin is required for inhibition of calcium oxalate crystallization. J Phys Chem B 112: 9151-9157, 2008.
65. Yang W, Harris SE, Raw P, Feng J, Gluhak-Heinrich J. MEPE overexpres-sion in osteocytes of Dmp1 null mice by activation of the PKA/CREB pathway (Meeting Abstract). J Bone Miner Res 21: S136-S136, 2006.
66. Yuan B, Takaiwa M, Clemens TL, Feng JQ, Kumar R, Rowe PS, Xie Y, Drezner MK. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest 118: 722-734, 2008.